Ultragenyx Pharmaceutical (RARE) Payables (2013 - 2026)
Ultragenyx Pharmaceutical (RARE) posted quarterly Payables of $42.0 million for Q1 2026, down 11.49% year-over-year from $47.4 million in Q1 2025, and up 35.48% quarter-over-quarter from $31.0 million in Q4 2025.
Ultragenyx Pharmaceutical (RARE) Payables (2013 - 2026) Analysis & Trends
Ultragenyx Pharmaceutical (RARE) has reported Payables for 14 consecutive years, with $42.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Payables fell 11.49% year-over-year to $42.0 million; the TTM figure through Mar 2026 stood at $42.0 million (down 11.49% YoY), while the FY2025 annual figure was $31.0 million, down 20.51% from the prior year.
- Payables advanced to $42.0 million in Q1 2026 per RARE's latest filing, from $31.0 million in the prior quarter.
- Across five years, Payables topped out at $59.8 million in Q2 2024 and bottomed at $23.5 million in Q3 2022.
- Historically, Payables has averaged $39.5 million across 5 years, with a median of $40.6 million in 2025.
- Annual changes were most pronounced in 2022 — Payables surged 152.5% — and 2025, when it plunged 42.75%.
- Ultragenyx Pharmaceutical's Payables stood at $43.3 million in 2022, then retreated by 2.68% to $42.1 million in 2023, then retreated by 7.39% to $39.0 million in 2024, then dropped by 20.51% to $31.0 million in 2025, then soared by 35.48% to $42.0 million in 2026.
- Business Quant data shows RARE's Payables at $42.0 million in Q1 2026, $31.0 million in Q4 2025, and $40.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Ultragenyx Pharmaceutical | 2.61 Bn | 2.33 Bn | 180.00 Mn | 39.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 39.00 Mn |
| Mar 31, 2026 | 42.00 Mn |
| Dec 31, 2025 | 31.00 Mn |
| Sep 30, 2025 | 40.57 Mn |
| Jun 30, 2025 | 34.24 Mn |
| Mar 31, 2025 | 47.45 Mn |
| Dec 31, 2024 | 39.00 Mn |
| Sep 30, 2024 | 35.99 Mn |
| Jun 30, 2024 | 59.81 Mn |
| Mar 31, 2024 | 40.97 Mn |
| Dec 31, 2023 | 42.11 Mn |
| Sep 30, 2023 | 33.36 Mn |
| Jun 30, 2023 | 42.12 Mn |
| Mar 31, 2023 | 58.98 Mn |
| Dec 31, 2022 | 43.27 Mn |
| Sep 30, 2022 | 23.53 Mn |
| Jun 30, 2022 | 34.21 Mn |
| Mar 31, 2022 | 23.69 Mn |
| Dec 31, 2021 | 17.14 Mn |
| Sep 30, 2021 | 15.58 Mn |